Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion

Talitha Van Der Meulen, Cynthia J. Donaldson, Elena Cáceres, Anna E. Hunter, Christopher Cowing-Zitron, Lynley D. Pound, Michael W. Adams, Andreas Zembrzycki, Kevin Grove, Mark O. Huising

    Research output: Contribution to journalArticle

    59 Citations (Scopus)

    Abstract

    The peptide hormone urocortin3 (Ucn3) is abundantly expressed by mature beta cells, yet its physiological role is unknown. Here we demonstrate that Ucn3 is stored and co-released with insulin and potentiates glucose-stimulated somatostatin secretion via cognate receptors on delta cells. Further, we found that islets lacking endogenous Ucn3 have fewer delta cells, reduced somatostatin content, impaired somatostatin secretion, and exaggerated insulin release, and that these defects are rectified by treatment with synthetic Ucn3 in vitro. Our observations indicate that the paracrine actions of Ucn3 activate a negative feedback loop that promotes somatostatin release to ensure the timely reduction of insulin secretion upon normalization of plasma glucose. Moreover, Ucn3 is markedly depleted from beta cells in mouse and macaque models of diabetes and in human diabetic islets. This suggests that Ucn3 is a key contributor to stable glycemic control, whose reduction during diabetes aggravates glycemic volatility and contributes to the pathophysiology of this disease.

    Original languageEnglish (US)
    Pages (from-to)769-776
    Number of pages8
    JournalNature Medicine
    Volume21
    Issue number7
    DOIs
    StatePublished - Jul 9 2015

    Fingerprint

    Somatostatin
    Feedback control
    Insulin
    Feedback
    Somatostatin-Secreting Cells
    Medical problems
    Glucose
    Volatilization
    Peptide Hormones
    Macaca
    Plasmas
    Defects

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)
    • Medicine(all)

    Cite this

    Van Der Meulen, T., Donaldson, C. J., Cáceres, E., Hunter, A. E., Cowing-Zitron, C., Pound, L. D., ... Huising, M. O. (2015). Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nature Medicine, 21(7), 769-776. https://doi.org/10.1038/nm.3872

    Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. / Van Der Meulen, Talitha; Donaldson, Cynthia J.; Cáceres, Elena; Hunter, Anna E.; Cowing-Zitron, Christopher; Pound, Lynley D.; Adams, Michael W.; Zembrzycki, Andreas; Grove, Kevin; Huising, Mark O.

    In: Nature Medicine, Vol. 21, No. 7, 09.07.2015, p. 769-776.

    Research output: Contribution to journalArticle

    Van Der Meulen, T, Donaldson, CJ, Cáceres, E, Hunter, AE, Cowing-Zitron, C, Pound, LD, Adams, MW, Zembrzycki, A, Grove, K & Huising, MO 2015, 'Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion', Nature Medicine, vol. 21, no. 7, pp. 769-776. https://doi.org/10.1038/nm.3872
    Van Der Meulen T, Donaldson CJ, Cáceres E, Hunter AE, Cowing-Zitron C, Pound LD et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nature Medicine. 2015 Jul 9;21(7):769-776. https://doi.org/10.1038/nm.3872
    Van Der Meulen, Talitha ; Donaldson, Cynthia J. ; Cáceres, Elena ; Hunter, Anna E. ; Cowing-Zitron, Christopher ; Pound, Lynley D. ; Adams, Michael W. ; Zembrzycki, Andreas ; Grove, Kevin ; Huising, Mark O. / Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. In: Nature Medicine. 2015 ; Vol. 21, No. 7. pp. 769-776.
    @article{9de4b43c71f945b7bd25d64ff4457ddb,
    title = "Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion",
    abstract = "The peptide hormone urocortin3 (Ucn3) is abundantly expressed by mature beta cells, yet its physiological role is unknown. Here we demonstrate that Ucn3 is stored and co-released with insulin and potentiates glucose-stimulated somatostatin secretion via cognate receptors on delta cells. Further, we found that islets lacking endogenous Ucn3 have fewer delta cells, reduced somatostatin content, impaired somatostatin secretion, and exaggerated insulin release, and that these defects are rectified by treatment with synthetic Ucn3 in vitro. Our observations indicate that the paracrine actions of Ucn3 activate a negative feedback loop that promotes somatostatin release to ensure the timely reduction of insulin secretion upon normalization of plasma glucose. Moreover, Ucn3 is markedly depleted from beta cells in mouse and macaque models of diabetes and in human diabetic islets. This suggests that Ucn3 is a key contributor to stable glycemic control, whose reduction during diabetes aggravates glycemic volatility and contributes to the pathophysiology of this disease.",
    author = "{Van Der Meulen}, Talitha and Donaldson, {Cynthia J.} and Elena C{\'a}ceres and Hunter, {Anna E.} and Christopher Cowing-Zitron and Pound, {Lynley D.} and Adams, {Michael W.} and Andreas Zembrzycki and Kevin Grove and Huising, {Mark O.}",
    year = "2015",
    month = "7",
    day = "9",
    doi = "10.1038/nm.3872",
    language = "English (US)",
    volume = "21",
    pages = "769--776",
    journal = "Nature Medicine",
    issn = "1078-8956",
    publisher = "Nature Publishing Group",
    number = "7",

    }

    TY - JOUR

    T1 - Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion

    AU - Van Der Meulen, Talitha

    AU - Donaldson, Cynthia J.

    AU - Cáceres, Elena

    AU - Hunter, Anna E.

    AU - Cowing-Zitron, Christopher

    AU - Pound, Lynley D.

    AU - Adams, Michael W.

    AU - Zembrzycki, Andreas

    AU - Grove, Kevin

    AU - Huising, Mark O.

    PY - 2015/7/9

    Y1 - 2015/7/9

    N2 - The peptide hormone urocortin3 (Ucn3) is abundantly expressed by mature beta cells, yet its physiological role is unknown. Here we demonstrate that Ucn3 is stored and co-released with insulin and potentiates glucose-stimulated somatostatin secretion via cognate receptors on delta cells. Further, we found that islets lacking endogenous Ucn3 have fewer delta cells, reduced somatostatin content, impaired somatostatin secretion, and exaggerated insulin release, and that these defects are rectified by treatment with synthetic Ucn3 in vitro. Our observations indicate that the paracrine actions of Ucn3 activate a negative feedback loop that promotes somatostatin release to ensure the timely reduction of insulin secretion upon normalization of plasma glucose. Moreover, Ucn3 is markedly depleted from beta cells in mouse and macaque models of diabetes and in human diabetic islets. This suggests that Ucn3 is a key contributor to stable glycemic control, whose reduction during diabetes aggravates glycemic volatility and contributes to the pathophysiology of this disease.

    AB - The peptide hormone urocortin3 (Ucn3) is abundantly expressed by mature beta cells, yet its physiological role is unknown. Here we demonstrate that Ucn3 is stored and co-released with insulin and potentiates glucose-stimulated somatostatin secretion via cognate receptors on delta cells. Further, we found that islets lacking endogenous Ucn3 have fewer delta cells, reduced somatostatin content, impaired somatostatin secretion, and exaggerated insulin release, and that these defects are rectified by treatment with synthetic Ucn3 in vitro. Our observations indicate that the paracrine actions of Ucn3 activate a negative feedback loop that promotes somatostatin release to ensure the timely reduction of insulin secretion upon normalization of plasma glucose. Moreover, Ucn3 is markedly depleted from beta cells in mouse and macaque models of diabetes and in human diabetic islets. This suggests that Ucn3 is a key contributor to stable glycemic control, whose reduction during diabetes aggravates glycemic volatility and contributes to the pathophysiology of this disease.

    UR - http://www.scopus.com/inward/record.url?scp=84936891662&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84936891662&partnerID=8YFLogxK

    U2 - 10.1038/nm.3872

    DO - 10.1038/nm.3872

    M3 - Article

    C2 - 26076035

    AN - SCOPUS:84936891662

    VL - 21

    SP - 769

    EP - 776

    JO - Nature Medicine

    JF - Nature Medicine

    SN - 1078-8956

    IS - 7

    ER -